文献速递产科母胎医学

胎盘生长因子与不良新生儿及母体结局风险

Placental Growth Factor and the Risk of Adverse Neonatal and Maternal Outcomes.
PubMed 文献 · Obstet Gynecol · 2020-01-01

本研究为PETRA试验的二次分析,纳入1112例疑似子痫前期孕妇,评估血浆胎盘生长因子(PlGF)异常与不良新生儿及母体结局的关联。结果显示低PlGF(≤100 pg/mL)与复合新生儿结局(aRR 17.2)及母体结局(aRR 3.6)风险显著增加相关,正常PlGF时不良结局罕见,提示PlGF可用于风险分层。

要点

  • 低PlGF(≤100 pg/mL)与复合新生儿结局风险显著增加相关(aRR 17.2)。
  • 低PlGF与复合母体结局风险显著增加相关(aRR 3.6)。
  • 低PlGF对不良结局阴性预测值高(新生儿99.2%,母体98.1%)。

核心结论

  • 在疑似子痫前期孕妇中,PlGF异常者发生不良新生儿和母体结局的风险显著更高。
  • PlGF正常时这些不良结局少见,提示PlGF或可用于风险分层。

研究设计与样本

  • 本研究为PETRA试验的二次分析,PETRA为前瞻性多中心观察性研究,纳入疑似子痫前期孕妇。
  • 分析纳入年龄18-45岁、单胎妊娠20-41周的1112例孕妇,检测入组时血浆PlGF。
  • 异常PlGF定义为低(≤100 pg/mL)或极低(<12 pg/mL)。

主要发现

  • 1112例中,低PlGF者742例(67%),极低PlGF者353例(32%)。
  • 复合不良新生儿结局总体发生率6.4%,复合不良母体结局总体发生率4.8%。
  • 与正常PlGF(>100 pg/mL)相比,低PlGF与复合新生儿结局风险增加相关(9.2% vs 0.8%;aRR 17.2,95% CI 5.2-56.3)。
  • 低PlGF与复合母体结局风险增加相关(6.2% vs 1.9%;aRR 3.6,95% CI 1.7-8.0)。
  • 极低PlGF同样与新生儿和母体结局显著相关。

关键数值与推荐

  • 低PlGF对复合新生儿结局的敏感性95.8%、特异性35.3%,阳性预测值9.2%,阴性预测值99.2%。
  • 低PlGF对复合母体结局的敏感性86.8%、特异性34.3%,阳性预测值6.2%,阴性预测值98.1%。

临床怎么用

  • 对疑似子痫前期孕妇,可检测血浆PlGF辅助风险分层。
  • 低PlGF提示不良新生儿和母体结局风险增加,需加强监测。
  • 正常PlGF时不良结局发生率低,阴性预测价值高。

局限性

  • 本研究为二次分析,原始PETRA试验由Alere资助,但本研究未获资助。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether abnormal plasma placental growth factor (PlGF) level is associated with adverse neonatal and maternal outcomes. METHODS: This was a secondary analysis of the Preeclampsia Triage by Rapid Assay Trial (PETRA), a prospective, multicenter, observational study that enrolled women with suspected preeclampsia. Our analysis included women age 18-45 years with a singleton pregnancy between 20 and 41 weeks of gestation. Plasma collected at enrollment was used for PlGF measurement. Abnormal PlGF was defined as low (100 pg/mL or less) or very low (less than 12 pg/mL). The primary outcomes were composite adverse neonatal and maternal outcomes. We used multivariable Poisson regression models to examine the association between PlGF and outcomes. RESULTS: Of 1,112 women who met the inclusion criteria, plasma PlGF was low in 742 (67%) and very low in 353 (32%). In the cohort, the overall rates of the composite adverse neonatal and maternal outcomes were 6.4% and 4.8%, respectively. Compared with normal PlGF (more than 100 pg/mL), low PlGF was significantly associated with an increased risk of the composite neonatal outcome (9.2% vs 0.8%; adjusted relative risk [aRR] 17.2, 95% CI 5.2-56.3), and the composite maternal outcome (6.2% vs 1.9%; aRR 3.6, 95% CI 1.7-8.0). Very low PlGF was also significantly associated with both neonatal and maternal outcomes. The sensitivity and specificity of low PlGF were 95.8% and 35.3%, respectively, for the composite neonatal outcome, and 86.8% and 34.3% for the composite maternal outcome. Although the positive predictive values were low (9.2% and 6.2%, respectively), the negative predictive value of low PlGF for neonatal and maternal outcomes was 99.2% and 98.1%, respectively. CONCLUSION: Among women being evaluated for preeclampsia, those with abnormal PlGF are significantly more likely to experience adverse neonatal and maternal outcomes. These outcomes occur infrequently when the PlGF is normal. These findings suggest that PlGF may be useful for risk stratification of women with suspected preeclampsia. FUNDING SOURCE: No funding was received for this study. The original PETRA study was supported by funding from Alere.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Parchem JG, Brock CO, Chen HY, et al. Placental Growth Factor and the Risk of Adverse Neonatal and Maternal Outcomes. Obstet Gynecol. 2020. PMID: 32028495. doi:10.1097/AOG.0000000000003694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。